checkAd
    Startseite > Aktien > Aurinia Pharmaceuticals > Nachrichten
    Aurinia Pharmaceuticals Aktie
    5,2000
     
    USD
    +2,16 %
    +0,1100 USD
    Letzter Kurs 01.05.24 Nasdaq
    5,1900
     
    USD
    8.200 STK
    Geldkurs 01.05.24
    5,2100
     
    USD
    4.500 STK
    Briefkurs 01.05.24
    ISIN: CA05156V1022 · WKN: A1W7D4 · SYM: AUPH · Kanada

    Neueste Nachrichten

    Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
    01.05.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
    30.04.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    16.04.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
    15.04.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
    09.04.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
    29.02.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia to Participate in Upcoming Investor Healthcare Conferences
    27.02.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
    15.02.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
    05.02.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
    05.01.24 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
    20.12.23 · Business Wire (engl.) · Aurinia Pharmaceuticals
    Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan
    13.11.23 · Business Wire (engl.) · Aurinia Pharmaceuticals